Lawsuit Filed Over Hemophilia Drug

Law360, New York (August 24, 2006, 12:00 AM EDT) -- Wyeth subsidiary Genetics Institute has sued Baxter Healthcare Corp. for breach of contract regarding the hemophilia drug Recombinate.

The complaint, originally filed under seal in Delaware Chancery Court on Aug. 4, accused Baxter of backing out of a joint agreement in order to promote its own hemophilia drug Advate.

“As a result of Baxter’s breaches of contract, GI has suffered substantial damage,” Genetics Institute said.

Starting in 1989, Genetics Institute agreed to supply Baxter with Factor VIII, the protein necessary to form blood clots. Baxter then...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.